

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number
WO 2005/000332 A2

- (51) International Patent Classification⁷: A61K 38/00
- (74) Agent: TAKASHIMA, Hajime; Fujimura Yamato Seimei Bldg., 2-14, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0044 (JP).
- (21) International Application Number:
PCT/JP2004/009371
- (22) International Filing Date: 25 June 2004 (25.06.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
2003-183643 27 June 2003 (27.06.2003) JP
- (71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ITO, Tatsuo [JP/JP]; c/o Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University, 5-1, Shikata-cho 2-chome, Okayama-shi, Okayama 700-8558 (JP). OZAKI, Toshifumi [JP/JP]; c/o Department of Orthopaedic Surgery Okayama University Hospital, 5-1, Shikata-cho 2-chome, Okayama-shi, Okayama 700-8558 (JP). OUCHIDA, Mamoru [JP/JP]; c/o Department of Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University, 5-1, Shikata-cho 2-chome, Okayama-shi, Okayama 700-8558 (JP).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2005/000332 A2

(54) Title: THERAPEUTIC AGENT FOR SOFT TISSUE SARCOMA

(57) Abstract: The present invention relates to a therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma), which contains a histone deacetylase inhibitor (particularly compound A) as an active ingredient.

DESCRIPTION
THERAPEUTIC AGENT FOR SOFT TISSUE SARCOMA


Technical Field

The present invention relates to a therapeutic agent for soft tissue sarcoma, which contains a histone deacetylase inhibitor as an active ingredient.


Background Art

In general, when there is a report on a substance or a compound having an antitumor activity and the report is based solely on *in vitro* results, it has been pointed out that such reported results do not directly suggest *in vivo* results. In other words, a substance showing an antitumor activity *in vitro* does not necessarily show an antitumor activity *in vivo*, and application of a substance showing an antitumor activity *in vitro* directly as an antitumor agent is difficult.

For example, it has been reported that a compound represented by the formula (I)



(hereinafter to be also referred to as compound A; SEQ ID; No 1), particularly a stereoisomer of the formula (II)



(hereinafter to be also referred to as compound B or FK2228), selectively inhibits histone deacetylase to derive a potent antitumor activity, and that this substance causes high
5 acetylation of histone in the treated cells, thereby inducing transcription-regulatory activity of various genes, cell cycle inhibitory activity and apoptosis (e.g., JP-B-7-64872 (corresponding to US Patent No.4977138), "Experimental Cell Research", US (1998), vol. 241, pp. 126-133). As the situation
10 now stands, however, there are many problems yet to be solved, such as whether or not *in vitro* results are directly applicable *in vivo*, whether or not a useful *in vivo* effect can be afforded in any tumor, and the like. No report has ever verified *in vitro* and *in vivo* antitumor activities against
15 soft tissue sarcoma (particularly synovial sarcoma) of the present invention.

Histone deacetylase is a metallo-deacetylating enzyme coordinating Zn at an active center (M.S. Finnin et al., Nature, 401, 188-193 (1999)). This enzyme is considered to
20 change affinity of various acetylated histones for DNA. The direct biological phenomenon brought thereby is a change in the chromatin structure. The minimum unit of the chromatin structure is a nucleosome wherein 146 bp DNA is wound 1.8 times anticlockwise around a histone octamer (H2A, H2B, H3 and
25 H4, each 2 molecules, core histone). The core histone

stabilizes the nucleosome structure by interaction of the positive charge of the N-terminus of each histone protein with DNA. Acetylation of histone is controlled by the equilibrium between an acetylation reaction involving histone

5 acetyltransferase and a deacetylation reaction involving histone deacetylase. It is considered that the histone acetylation occurs at a lysin residue where the histone protein N-terminus is evolutionally preserved well, due to which a core histone protein loses charges at the N-terminus,

10 interaction with DNA is attenuated, and the structure of nucleosome becomes unstable. Accordingly, the histone deacetylation is considered to be the reverse thereof, namely, a shift toward stabilization of the nucleosome structure. However, to what degree the acetylation changes the chromatin

15 structure and how it relates to the transcriptional regulation etc. secondarily induced thereby are unclear in many aspects.

As genetic characteristics of synovial sarcoma, it has been reported that, in about 97% of the entire synovial sarcomas, SYT gene present in the 18th chromosome and SSX gene

20 present on the X chromosome are fused due to chromosomal translocation t (18,X) to express a chimera protein called SYT-SSX, and SYT protein constituting the N-terminal region of this protein is bound with a chromatin remodeling-associated protein such as p300 and BRM to form a complex (Josiane E. Eid

25 et al., Cell, 102, 839-848 (2000)). Synovial sarcoma is one kind of soft tissue sarcoma developed in the four limbs and trunk of the body of males and females, and its primary therapy includes removal of tumor by operation and chemotherapy before and after the operation. However,

30 chemotherapy is associated with poor prognosis and a five-year survival rate is about 60-70%. Thus, an effective cure has not been established as yet.

Disclosure of the Invention

An object of the present invention is to provide a therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma), which contains a histone deacetylase inhibitor, particularly compound A, compound B, its reduction products, metabolites, derivatives, prodrugs, and other analogs known to have a strong histone deacetylase inhibitory activity, or a pharmaceutically acceptable salt thereof, as an active ingredient.

10 In an attempt to solve the above-mentioned problems, the present inventors have considered that, in synovial sarcoma, formation of the aforementioned complex of SYT-SSX protein, a chromatin remodeling-associated protein and histone deacetylase (HDAC)-associated protein enhances histone
15 deacetylase activity, which in turn has an effect on the canceration, development and/or proliferation, of synovial sarcoma, and have conducted intensive studies of the effect of histone deacetylase inhibition on various synovial sarcoma cell strains (HS-SY-2, YaFuSS, SYO-1) that express SYT-SSX
20 protein. As a result, they have found that compound B and tricostatin A, which are histone deacetylase inhibitors, exhibit a potent antitumor activity *in vitro* and *in vivo* against SYT-SSX protein expressing cells. Furthermore, they have found that they also exhibit a potent antitumor activity
25 against a synovial sarcoma cell strain (HTB93) not expressing SYT-SSX protein. Accordingly, the present invention provides the following.

- (1) A therapeutic agent for soft tissue sarcoma, which comprises a histone deacetylase inhibitor as an active
30 ingredient.
- (2) The therapeutic agent of the above-mentioned (1), wherein the soft tissue sarcoma is synovial sarcoma.
- (3) The therapeutic agent of the above-mentioned (1) or (2),

wherein the soft tissue sarcoma or synovial sarcoma is an SYT-SSX protein expressing sarcoma.

(4) The therapeutic agent of the above-mentioned (1), wherein the histone deacetylase inhibitor is compound A or compound B,
5 or a reduced form thereof, an analog thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof.

(5) The therapeutic agent of the above-mentioned (4), wherein the soft tissue sarcoma is synovial sarcoma.

(6) The therapeutic agent of the above-mentioned (5), wherein
10 the synovial sarcoma is SYT-SSX protein expressing sarcoma.

(7) A pharmaceutical composition for the treatment of soft tissue sarcoma, which comprises a histone deacetylase inhibitor and a pharmaceutically acceptable carrier.

(8) The pharmaceutical composition of the above-mentioned (7),
15 wherein the histone deacetylase inhibitor is compound A or compound B, or a reduced form thereof, an analog thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof.

(9) A method for treating soft tissue sarcoma, synovial sarcoma, or an SYT-SSX protein expressing sarcoma, which
20 comprises administering an effective amount of a histone deacetylase inhibitor.

(10) The method of the above-mentioned (9), wherein the histone deacetylase inhibitor is compound A or compound B, or a reduced form thereof, an analog thereof, a prodrug thereof
25 or a pharmaceutically acceptable salt thereof.

(11) Use of a histone deacetylase inhibitor for the production of a therapeutic agent for soft tissue sarcoma.

(12) The use of the above-mentioned (11), wherein the histone deacetylase inhibitor is compound A or compound B, or a
30 reduced form thereof, an analog thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof.

(13) A commercial package comprising the pharmaceutical composition of the above-mentioned (7) and a written matter

associated therewith, the written matter stating that said pharmaceutical composition can or should be used for the treatment of soft tissue sarcoma.

Brief Description of the Drawings

5 Fig. 1 is a graph showing an *in vitro* antitumor action of FK228 against HS-SY-2 synovial sarcoma cell strain, which is one of the SYT-SSX protein expressing synovial sarcoma cell strains.

Fig. 2 is a graph showing an *in vitro* antitumor action of
10 FK228 against YaFuSS synovial sarcoma cell strain, which is one of the SYT-SSX protein expressing synovial sarcoma cell strains.

Fig. 3 is a graph showing an *in vitro* antitumor action of
FK228 against SYO-1 synovial sarcoma cell strain, which is one
15 of the SYT-SSX protein expressing synovial sarcoma cell strains.

Fig. 4 is a graph showing an *in vivo* antitumor action of
FK228 against SYO-1 synovial sarcoma cell strain, which is one
of the SYT-SSX protein expressing synovial sarcoma cell
20 strains.

Fig. 5 is a graph showing an *in vitro* antitumor effect of
FK228 on HTB93 synovial sarcoma cell strain, which is one of
the synovial sarcoma cell strains that do not express SYT-SSX
protein.

25 Detailed Description of the Invention

The "histone deacetylase inhibitor", also referred to as "HDAC inhibitor" or "HDACi", in the present invention is a compound that binds to an active site of histone deacetylase competitively with substrates, and/or a compound that reduces
30 or inhibits the enzyme activity of histone deacetylase, and includes any compound (whether synthetic or natural) reported or will be reported in the future to have a histone deacetylase inhibitory activity. To be specific, the

aforementioned compound A, a salt thereof and a derivative thereof (e.g., acetylated compound A, thiol form (reduced form) with reduced S-S bond as described in WO02/06307, analogs thereof (e.g., compounds described in US Patent No. 5 6403555 etc.), prodrugs thereof, etc.) can be mentioned. In addition, Trichostatin A, sodium butyrate, suberoylanilide hydroxamic acid (SAHA), MS-275, cyclic hydroxamic-acid-containing peptide, Apicidin, Trapoxin and the like are the compounds reported to have a histone deacetylase inhibitory 10 activity.

While compound A (and other HDACi's) may have a stereoisomer (e.g., compound B) based on an asymmetric carbon atom or a double bond, such as an optically active form, a geometric isomer and the like, all these isomers and mixtures 15 thereof are also encompassed in the scope of the histone deacetylase inhibitor to be used in the present invention.

In the present specification, unless particularly specified, a simple reference to compound A means a group of compounds regardless of stereoisomerism, which include a 20 compound B represented by the formula (II).

Moreover, solvate compounds (e.g., inclusion compounds (e.g., hydrate etc.)), anhydrous forms, other crystal polymorphs and pharmaceutically acceptable salts thereof of HDACi's, such as compound A, compound B and salts thereof, are 25 also encompassed in the scope of the present invention.

The compound A or a salt thereof are known and available substances. For example, compound B, which is one of the stereoisomers of compound A, can be obtained by culturing a strain belonging to the genus *Chromobacterium*, which is 30 capable of producing compound B, under aerobic conditions, and harvesting the substance from its culture broth. As the strain belonging to the genus *Chromobacterium*, which is capable of producing compound B, for example, *Chromobacterium violaceum*

WB968 (FERM BP-1968) can be mentioned. More specifically, compound B can be obtained from a compound B producing strain as described in JP-B-7-64872 (corresponding to US Patent No. 4977138). The compound B is preferably harvested from a strain
5 belonging to the genus *Chromobacterium*, which is capable of producing compound B, because it can be obtained more easily. Synthetic or semi-synthetic compound B is also advantageous in that further purification step is not necessary or the number of steps can be reduced. Similarly, compounds A other than
10 compound B can be also obtained by semi-synthesis or total synthesis by conventionally known methods. To be more specific, it can be produced according to the method reported by Khan W. Li, et al. (J. Am. Chem. Soc., Vol. 118, 7237-7238(1996)).

A pharmaceutically acceptable salt of HDACi's, such as
15 the salt of compound A or compound B, includes salts with a base or an acid addition salt such as salts with inorganic base (e.g., alkali metal salts such as sodium salt, potassium salt etc., alkaline earth metal salts such as calcium salt, magnesium salt etc., ammonium salt), salts with an organic
20 base (e.g., organic amine salts such as triethylamine salt, diisopropylethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt etc.), inorganic acid addition salts (e.g., hydrochloride, hydrobromide, sulfate,
25 phosphate etc.), organic carboxylic acid or sulfonic acid addition salts (e.g., formate, acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate etc.), salts with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic
30 acid etc.) and the like.

In the present invention, *in vivo* and *in vitro* mean as they are generally used in this field. Namely, "*in vivo*" means a state where functions and reactions of the target living

organism can be expressed in living organisms, and "in vitro" means that such functions and reactions can be expressed in vitro (tissue culture system, cell culture system, cell-free system etc.).

5 Soft tissue sarcomas include malignant fibrous histocytoma, liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, fibrosarcoma, malignant schwannoma, angiosarcoma, clear cell sarcoma and the like.

 In addition, gene diagnosis of SYT-SSX protein expressing
10 synovial sarcoma enables selection of patients before treatment, for whom the histone deacetylase inhibitor of the present invention proves effective.

 The therapeutic agent for soft tissue sarcoma of the present invention can be used in the form of a pharmaceutical
15 preparation such as a solid, semisolid or liquid preparation (tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, liquid, emulsion, suspension, syrup, injection etc.) containing a histone deacetylase inhibitor as an active ingredient, which is suitable for transrectal,
20 intranasal, pulmonary, vaginal, external (topical), oral or parenteral (including subcutaneous, implantation, intravenous and intramuscular) administration.

 The therapeutic agent for soft tissue sarcoma of the present invention can be also produced by conventional methods
25 using various organic or inorganic carriers conventionally used for forming pharmaceutical preparations, such as excipients (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate etc.), condensation agents (e.g., cellulose, methyl cellulose,
30 hydroxypropyl cellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, starch etc.), disintegrants (e.g., starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, hydroxypropyl starch, sodium

starch glycolate, sodium hydrogen carbonate, calcium phosphate, calcium citrate etc.), lubricants (e.g., magnesium stearate, aerosil, talc, sodium lauryl sulfate etc.), corrigents (e.g., citric acid, menthol, glycine, orange powder etc.),

5 preservatives (e.g., sodium benzoate, sodium hydrogen sulfite, methylparaben, propylparaben etc.), stabilizers (citric acid, sodium citrate, acetic acid etc.), suspensions (e.g., methyl cellulose, polyvinyl pyrrolidone, aluminum stearate etc.), dispersants (e.g., hydroxypropylmethyl cellulose etc.),

10 diluents (e.g., water etc.), wax base materials (e.g., cacao butter, polyethylene glycol, white petrolatum etc.) and the like.

While the administration method of the therapeutic agent for soft tissue sarcoma of the present invention is not

15 particularly limited, intravenous, intramuscular or oral administration is preferable. In addition, while a therapeutically effective amount of HDACi's, such as, compound A or compound B or a pharmaceutically acceptable salt thereof, when it is used for a human as an active ingredient varies

20 depending on the age and condition of individual patient to be treated, and the kind of soft tissue sarcoma, in the case of an intravenous administration, the daily dose of compound A and compound B is generally 0.1-100 mg, preferably 1-50 mg, more preferably 5-30 mg, in the amount of compound A, per 1 m²

25 of human body surface area, which is given for the treatment of sarcoma by continuous infusion.

Furthermore, the HDACi's in the present invention can be administered alone or in combination with an additional anti-tumor treatment, such as surgery, radiation therapy and/or

30 chemotherapy. Examples of chemotherapeutic agents include DNA cross-linkers, alkylating antitumor agents, antimetabolite antitumors, and taxanes. Preferred chemotherapeutic agents include cisplatin, 5-fluorouracil, paclitaxel(taxol),

docetaxel, and the like.

Examples

The present invention is specifically explained in
5 detail in the following by referring to Examples, which are
not to be construed as limitative.

Example 1

An SYT-SSX protein expressing synovial sarcoma cell line
HS-SY-2 (established and kindly provided by Dr. Hiroshi Sonobe,
10 Department of Pathology, National Fukuyama Hospital), YaFuSS
(established and kindly provided by Dr. Junya Toguchida,
Department of Tissue Regeneration, Institute for Frontier
Medical Sciences, Kyoto University) and SYO-1 (established and
kindly provided by Dr. Akira Kawai, Department of Orthopedics,
15 Faculty of Medicine, Okayama University (now Department of
Orthopedics, National Cancer Center)) were cultured in DMEM
(Dulbecco's modified Eagle's medium) containing 10%(v/v) fetal
bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml
streptomycin at 37°C under 5% CO₂ environment. These cells
20 were plated and cultured for 24 hr, detached with 0.25%(w/v)
trypsin and recovered. For cell growth ability, an MTT
analysis kit (Colorimetric (MTT) assay for cell survival and
proliferation kit of CHEMICON International, Inc.) was used.
Each cell strain was plated in a 96 well microtiter plate at
25 10³ cell/well, and after culture for 24 hr, exposed to a
0.1%(v/v) dilute ethanol solution of FK228 at a concentration
distribution of 0.1 nM, 0.2 nM, 1 nM, 50 nM and 100 nM, and
0.1%(v/v) ethanol (Et-OH 0.1% in Fig. 1) as a control. After
exposure for 24 hr, 48 hr and 96 hr, each culture was passed
30 through a 570 nM filter and the absorbance was measured. All
were performed with n=4.

The results are shown in Fig. 1, Fig. 2 and Fig. 3.
FK228 showed an *in vitro* antitumor effect on SYT-SSX protein

expressing synovial sarcoma, a soft tissue sarcoma.

Example 2

Inbred male (BALB/C/nu/nu) nude mice were supplied by Charles River Japan, Inc. The animals were all fed and handled according to the Animal Test Guideline, Animal Resources Division, Advanced Science Research Center, Okayama University. FK228 was administered after 10 days from subcutaneous implantation of 10^5 cells each of the SYO-1 cell strain. The tumor volume was assumed by measuring two diameters perpendicular to each other using calipers and from the following formula (tumor volume= $1/6\pi [(d1 \times d2)^{3/2}]$ (wherein d1 and d2 are two perpendicular diameters)). The dose was evaluated by intravenously administering a dilute FK228 solution (50 μ l, 10% HCO60, diluted with physiological saline) at 0 mg/kg, 1.6 mg/kg or 3.2 mg/kg to 20 animals, and as a control, a 3.2 mg/kg dilute FK228 solution was intravenously injected to 7 animals free of tumor implantation. The administration was performed 3 times every 4 days, the tumor volume was also measured every 4 days, as well as after completion of the administration.

The results are shown in Fig. 4, wherein the measurement days are shown in terms of the number of days after the subcutaneous implantation. FK228 showed an *in vivo* antitumor effect on SYT-SSX protein expressing synovial sarcoma, a soft tissue sarcoma.

Example 3

An SYT-SSX protein non-expressing synovial sarcoma cell line HTB93 (purchased from ATCC: American Type Culture Collection) was cultured in DMEM (Dulbecco's modified Eagle's medium) containing 10%(v/v) fetal bovine serum (FBS), 100 U/ml penicillin and 100 μ g/ml streptomycin at 37°C under 5% CO₂ environment. These cells were plated and cultured for 24 hr, detached with 0.25%(w/v) trypsin and recovered. For cell

growth ability, an MTT analysis kit (Colorimetric (MTT) assay for cell survival and proliferation kit of CHEMICON International, Inc.) was used. Each cell strain was plated in a 96 well microtiter plate at 2×10^3 cell/well, and after 5 culture for 24 hr, exposed to a 0.1%(v/v) dilute ethanol solution of FK228 at a concentration distribution of 0.001 nM, 0.01 nM, 0.1 nM, 0.5 nM, 1 nM, 5 nM, 10 nM, 50 nM and 100 nM, 0.1%(v/v) ethanol as a control and the medium alone as a blank. After exposure for 24 hr, 48 hr, 72 hr and 96 hr, each culture 10 was passed through a 570 nm filter and the absorbance was measured. All were performed with n=4.

For the results, average values of the FK228 addition sample, control and blank were taken, and using numerical values obtained by subtracting a blank value from the value of 15 the FK228 addition sample or control, a percentage corresponding to the ratio of the numerical value of the FK228 addition sample relative to that of the control was taken as survival rate (%). The results are shown in Fig. 5. FK228 showed an *in vitro* antitumor effect also on SYT-SSX protein 20 non-expressing synovial sarcoma, which is one kind of soft tissue sarcoma.

Sequence Listing Free Text

SEQ ID; No 1: Xaa is an amino acid represented by the formula 25 $\text{NH}_2\text{C}(\text{CHCH}_3)\text{COOH}$.

In the formula $\text{COOHCH}_2\text{CH}(\text{CHCHC}_2\text{H}_4\text{SH})\text{OH}$, the carboxylic group is bonded with the amino group of the first amino acid Val, the hydroxyl group is bonded with the carboxylic group of the fourth amino acid Val, and the SH group is bonded with the 30 SH group of the second amino acid Cys via a disulfide bond.

Industrial Applicability

The therapeutic agent for soft tissue sarcoma of the


present invention, which contains a histone deacetylase inhibitor (particularly FK228) as an active ingredient, has a superior antitumor action not only *in vitro* but also *in vivo*. Accordingly, it can be clinically used, particularly
5 preferably for the treatment of soft tissue sarcoma.

While this invention has been shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes
10 in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. All patents and patent publication and other publications identified or referenced herein are incorporated
by reference in their entirety.

15 This application is based on and claims the benefit of patent application No. 183643/2003 filed in Japan, the contents of which are hereby incorporated by reference.

CLAIMS

1. A therapeutic agent for soft tissue sarcoma, which comprises a histone deacetylase inhibitor as an active ingredient.
2. The therapeutic agent of claim 1, wherein the soft tissue sarcoma is synovial sarcoma.
3. The therapeutic agent of claim 2, wherein the synovial sarcoma is SYT-SS protein expressing sarcoma.
4. The therapeutic agent of claim 1, wherein the histone deacetylase inhibitor is a compound represented by the formula (I)




or a reduced form thereof, an analog thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof.

5. The therapeutic agent of claim 4, wherein the soft tissue sarcoma is synovial sarcoma.
6. The therapeutic agent of claim 5, wherein the synovial

sarcoma is SYT-SSX protein expressing sarcoma.

7. A pharmaceutical composition for the treatment of soft tissue sarcoma, which comprises a histone deacetylase inhibitor and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7, wherein the histone deacetylase inhibitor is a compound represented by the formula (I)



10

or a reduced form thereof, an analog thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof.

9. A method for treating soft tissue sarcoma, which comprises administering an effective amount of a histone deacetylase inhibitor.

10. The method of claim 9, wherein the soft tissue sarcoma is synovial sarcoma.


11. The method of claim 10, wherein the synovial sarcoma is SYT-SSX protein expressing sarcoma.

12. The method of claim 9, wherein the soft tissue sarcoma is

selected from the group consisting of malignant fibrous histiocytoma, liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, fibrosarcoma, malignant schwannoma, angiosarcoma, and clear cell sarcoma.

5

13. The method of claim 9, wherein the histone deacetylase inhibitor is a compound represented by the formula (I)



10

or a reduced form thereof, an analog thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof.

14. The method of claim 13, wherein the soft tissue sarcoma is synovial sarcoma.

15. The method of claim 14, wherein the synovial sarcoma is SYT-SSX protein expressing sarcoma.

20 16. The method of claim 13, wherein the soft tissue sarcoma is selected from the group consisting of malignant fibrous histiocytoma, liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, fibrosarcoma, malignant schwannoma, angiosarcoma, and clear cell sarcoma.

25

17. The method of claim 9, wherein the histone deacetylase inhibitor is SAHA or trichostatin A.

18. The method of claim 17, wherein the soft tissue sarcoma is
5 synovial sarcoma.


19. The method of claim 18, wherein the synovial sarcoma is SYT-SSX protein expressing sarcoma.

10 20. The method of claim 17, wherein the soft tissue sarcoma is selected from the group consisting of malignant fibrous histocytoma, liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, fibrosarcoma, malignant schwannoma, angiosarcoma, and clear cell sarcoma.

15

21. Use of a histone deacetylase inhibitor for the production of a therapeutic agent for soft tissue sarcoma.

22. The use of claim 21, wherein the histone deacetylase
20 inhibitor is a compound represented by the formula (I)



or a reduced form thereof, an analog thereof, a prodrug
25 thereof or a pharmaceutically acceptable salt thereof.

23. A commercial package comprising the pharmaceutical
composition of claim 7 and a written matter associated
therewith, the written matter stating that said pharmaceutical
5 composition can or should be used for the treatment of soft
tissue sarcoma.

FIG 1




FIG 2




FIG 3




FIG 4





FIG 5



SEQUENCE LISTING

<110> Fujisawa Pharmaceutical Co., Ltd.

<120> Therapeutic agent for soft tissue sarcoma

<130> 09652

<150> JP 2003-183643

<151> 2003-06-27

<160> 1

<210> 1

<211> 4

<212> PRT

<213> Chromobacterium sp.

<220>

<221> MISC_FEATURE

<222> (3)

<223> Xaa is an amino acid represented by the formula
 $\text{NH}_2\text{C}(\text{CHCH}_3)\text{COOH}$.

<220>

<221> SITE

<222> (1), (2), (4)

<223> In the formula $\text{COOHCH}_2\text{CH}(\text{CHCH}_2\text{H}_4\text{SH})\text{OH}$, the carboxylic group is bonded with the amino group of the first amino acid Val, the hydroxyl group is bonded with the carboxylic group of the fourth amino acid Val, and the SH group is bonded with the SH group of the second amino acid Cys via a disulfide bond.

<400> 1

Val Cys Xaa Val

1